Among the priorities for research that would establish or refute NAT, we suggest reinforcing strategies that would partially eliminate cancer cells in order to retain immune-sensitive tumor cells that would outcompete immune-resistant tumor cells, for instance, by targeting the tumor stroma instead of only targeting cancer cells. The gene discussed is BRD2; the disease is neoplasm.